Deja vu? Ah...... it was approved 2 months ago in the EU. This was the FDA.
Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
**************************** An aside; This continues to only improve as the easiest, fastest HCV treatment. There are still huge numbers to treat, and the ability to prescribe and start treating w/o genotyping, doing viral load tests, without needing higher competency in treating physicians seems like the market share may continue to grow.
I WONDER? Seeing how successful this treatment has become, seeing a long treatment tail, I wonder what would have happened if somehow ENTA had been able to have paid for half the trials? What kind of money would they have spent, versus what they might currently be making, now, and in the future?
News 
Market Data 
Discover 
